The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The human white adipose tissue (WAT) contains progenitors with cooperative roles in breast cancer (BC) angiogenesis, local and metastatic progression. The biguanide Metformin (Met), commonly used for Type 2 diabetes, might have activity against BC and was found to inhibit angiogenesis in vivo . We studied Met and another biguanide, phenformin (Phe), in vitro and in vivo in BC models. In vitro , biguanides activated AMPK, inhibited Complex 1 of the respiratory chain and induced apoptosis of BC and WAT endothelial cells. In coculture, biguanides inhibited the production of several angiogenic proteins. In vivo , biguanides inhibited local and metastatic growth of triple negative and HER2+ BC in immune‐competent and immune‐deficient mice orthotopically injected with BC. Biguanides inhibited local and metastatic BC growth in a genetically engineered murine model model of HER2+ BC. In vivo , biguanides increased pimonidazole binding (but not HIF‐1 expression) of WAT progenitors, reduced tumor microvessel density and altered the vascular pericyte/endothelial cell ratio, so that cancer vessels displayed a dysplastic phenotype. Phe was significantly more active than Met both in vitro and in vivo . Considering their safety profile, biguanides deserve to be further investigated for BC prevention in high‐risk subjects, in combination with chemo and/or targeted therapy and/or as post‐therapy consolidation or maintenance therapy for the prevention of BC recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710 · cited 1×
“A recent study investigated the metabolic determinants of cancer cell sensitivity to glucose limitations and biguanides.(45) Mitochondrial oxidative phosphorylation (OXPHOS) was found to be crucial for optimal proliferation in low glucose.”
BackgroundHirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440
Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., & Marini, F. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030563 · Cited by 371
Zhang, Y., Daquinag, A., Traktuev, D. O., Amaya-Manzanares, F., Simmons, P. J., March, K. L., Pasqualini, R., Arap, W., & Kolonin, M. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3444 · Cited by 331
Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285 · cited 1×
“In recent studies, long-term Met treatment extended health and lifespan in mice.(46,47) This effect was possibly obtained mimicking the benefits of calorie restriction, such as reduced cancer development, improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol…”
BackgroundZhang, Y., Daquinag, A. C., Amaya-Manzanares, F., Sirin, O., Tseng, C., & Kolonin, M. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0294 · Cited by 233
Rowan, B. G., Gimble, J. M., Sheng, M., Anbalagan, M., Jones, R. K., Frazier, T. P., Asher, M., Lacayo, E. A., Friedlander, P. L., Kutner, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089595 · Cited by 174
Cited by
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“It inhibits angiogenesis (151) and therefore may reduce cancer metastasis.”
BackgroundThe future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Self-citationEndothelial Cell Metabolism in Health and Disease
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., & Carmeliet, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 335
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Self-citationMallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 260
Mechanism of antineoplastic activity of lonidamine
Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S.-C., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.001 · Cited by 205
“Similar effects might be produced by metformin that is Food and Drug Administration (FDA) approved Complex I inhibitors (43-49).”
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity
Albini, A., Bruno, A., Gallo, C., Pajardi, G., Noonan, D. M., & Dallaglio, K. (2015) · Connective Tissue Research · doi:10.3109/03008207.2015.1066780 · Cited by 166
“Recently, significant attention has been given to biguanides, as drugs able to target both cancer and microenvironmental compartments (115,116).”
BackgroundSelf-citationTargeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
Navarro, P., Bueno, M. J., Zagorac, I., Mondejar, T., Sanchez, J., Mourón, S., Muñoz, J., Gómez-López, G., Jimenez-Renard, V., Mulero, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.052 · Cited by 102
“Finally, phenformin has been reported to directly influence endothelial cell survival (Orecchioni et al., 2015).”
BackgroundObesity and Cancer: An Angiogenic and Inflammatory Link
Fukumura, D., Incio, J., Shankaraiah, R. C., & Jain, R. K. (2016) · Microcirculation · doi:10.1111/micc.12270 · Cited by 69
Urra, F. A., Muñoz, F., Córdova-Delgado, M., Ramírez, M. P., Peña-Ahumada, B., Rios, M., Cruz, P., Ahumada-Castro, U., Bustos, G., Silva-Pavez, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31367-9 · Cited by 69
Metadata
- Authors
- Orecchioni, S., Reggiani, F., Talarico, G., Mancuso, P., Calleri, A., Gregato, G., Labanca, V., Noonan, D. M., Dallaglio, K., Albini, A., & Bertolini, F.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-09-18
- Volume
- 136
- Issue
- 6
- Pages
- E534-44
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1931273074
- Cited by
- 139
- References
- 12
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.